The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
We are pleased to present below all posts archived in 'August, 2018'. If you still can't find what you are looking for, try using the search box.
AMSBIO TUNR kits allows you to precisely tune gene expression from 100% all the way down to complete knockout, model ranges of gene expression reflecting diversity in patient populations and knockdown essential genes where knockout would result in lethality. In addition, a kit is available that allows you to control endogenous gene expression enabling elimination of artifacts from ectopic expression.
The TUNR Flexible Gene Editing System for Endogenous Genes is designed to generate four cell lines or animal models with four different levels of knockdown of your endogenous gene of interest.
The TUNR Targeted Transgenic kit enables you to insert your gene of interest under TUNR control into the AAVS1 locus. AAVS1 is a safe place to integrate transgenes, allowing predictable expression from a locus known not to alter the expression of other genes or have otherwise negative effects on the cell.
The TUNR Plasmid-Delivered Transgenes kit allows you to control the expression of a transgene. Using the kit, y ...
Read the rest of entry »
Disease associated chromosomal rearrangements often have break points located within disease causing genes or in their vicinity. The purpose of this study is to characterize a balanced reciprocal translocation in a girl with intellectual disability and seizures by positional cloning and whole genome sequencing. The translocation was identification by G- banding and confirmed by WCP FISH. Fine mapping using BAC clones and whole genome sequencing using Oxford nanopore long read sequencing technology for a 1.46 X coverage of the genome was done. The positional cloning showed split signals with BAC RP11-943 J20. Long read sequencing analysis of chimeric reads carrying parts of chromosomes X and 20 helped to identify the breakpoints to be in intron 2 of ARHGEF9 gene on Xp11.1 and on 20p13 between RASSF2 and SLC23A2 genes. This is the first report of translocation which successfully ...
We report a customized gene panel assay based on multiplex long-PCR followed by third generation sequencing on nanopore technology (MinION), designed to analyze five frequently mutated genes in chronic lymphocytic leukemia (CLL): TP53, NOTCH1, BIRC3, SF3B1 and MYD88. For this purpose, 12 patients were selected according to specific cytogenetic and molecular features significantly associated with their mutational status. In addition, simultaneous analysis of the targets genes was performed by molecular assays or Sanger Sequencing. Data analysis included mapping to the GRCh37 human reference genome, variant calling and annotation, and average sequencing depth/error rate analysis. The sequencing depth resulted on average higher for smaller amplicons, and the final breadth of coverage of the panel was 94.1%. The error rate was about 6% and 2% for insertions/deletions and single nucleotide variants, respectively. Our gene panel allows analysis of the prognostically relevant genes in CLL, with two PCRs per patient. ...
In the latest edition of Oxford Nanpore's newsletter please take a look at an article: Rapid Diagnosis of Lower Respiratory Infection using Nanopore-based Clinical Metagenomics
Lower respiratory tract infections are the leading cause of death from infectious disease worldwide, causing three million deaths in 2016. A wide range of pathogens cause these infections, making quick diagnosis and prescribing decisions a challenge.
Using the MinION, Charalampous et al. developed a pipeline that was capable of removing up to 99.99% of host nucleic acids from the clinical samples, was 96.6% concordant with culture in terms of pathogen detection, and could accurately detect resistance genes within six hours.
Read the workflow
We are delighted to announce our 2018 OBN Award Finalists. This is the 10th anniversary of the OBN Awards, the life sciences industry’s most highly regarded awards event. 2018 was another record breaking year, with award entries up over 40% on 2017.
It is not enough for companies to gain regulatory approval in order to gain market access. Almost all new pharmaceutical products need to undergo value assessment by reimbursement authorities to gain market access and return of investment. Almost every country now has such an authority in place, including the UK, Germany, France, Italy, Spain and the USA.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.